STOCK TITAN

Alamar Biosciences holders sell 100,117 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Reporting persons for Alamar Biosciences, Inc. (ALMR) reported sales of 100,117 common shares on November 11, 2026, held of record by Qiming Managing Directors Fund VI, L.P.; Qiming Venture Partners VI, L.P.; Qiming Venture Partners VIII Investments, LLC; and Qiming Venture Partners VIII-HC, L.P.

The seven reporting persons, each listed as a ten-percent owner, are those four entities plus Qiming Corporate GP VI, Ltd., Qiming GP VIII, LLC, and Qiming GP VIII-HC, LLC. The general partners may be deemed to have voting and dispositive power over the respective shares, but disclaim beneficial ownership except for proportionate pecuniary interests. No Rule 10b5-1 plan is reported.

Insider Qiming Corporate GP VI, Ltd., Qiming Managing Directors Fund VI, L.P., Qiming Venture Partners VI, L.P., Qiming GP VIII, LLC, Qiming Venture Partners VIII Investments, LLC, Qiming GP VIII-HC, LLC, Qiming Venture Partners VIII-HC, L.P.
Role 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner
Sold 100,117 shs ($2.94M)
Type Security Shares Price Value
Sale Common Stock F1, F2 1,694 $29.34 $50K
Sale Common Stock F3, F2 56 $30.63 $2K
Sale Common Stock F1, F4 62,944 $29.34 $1.85M
Sale Common Stock F3, F4 2,084 $30.63 $64K
Sale Common Stock F1, F5 14,687 $29.34 $431K
Sale Common Stock F3, F5 486 $30.63 $15K
Sale Common Stock F1, F6 17,584 $29.34 $516K
Sale Common Stock F3, F6 582 $30.63 $18K
Holdings After Transaction: Common Stock — 1,632,188 shares (Indirect, See footnote)
Footnotes (6)
  1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.40 to $30.22, inclusive. The reporting person undertakes to provide to Alamar Biosciences, Inc., any security holder of Alamar Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes (1) and (3) to this Form 4.
  2. F2. These shares are held of record by Qiming Managing Directors Fund VI, L.P. ("Qiming Managing Directors"). Qiming Corporate GP VI, Ltd. ("Qiming Corporate") serves as the general partner of Qiming Managing Directors and may be deemed to have voting and dispositive power over the shares held by Qiming Managing Directors. Qiming Corporate disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
  3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.38 to $30.94, inclusive.
  4. F4. These shares are held of record by Qiming Venture Partners VI, L.P., ("Qiming Venture Partners VI"). Qiming Corporate, through one intermediary, serves as the indirect general partner of Qiming Venture Partners VI and may be deemed to have voting and dispositive power over the shares held by Qiming Venture Partners VI. Qiming Corporate disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
  5. F5. These shares are held of record by Qiming Venture Partners VIII Investments, LLC ("QVP VIII LLC"). Qiming GP VIII, LLC, through two parallel intermediaries, serves as the indirect general partner of QVP VIII LLC and may be deemed to have voting and dispositive power over the shares held by QVP VIII LLC. Qiming GP VIII, LLC disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
  6. F6. These shares are held of record by Qiming Venture Partners VIII-HC, L.P. ("QVP VIII-HC"). Qiming GP VIII-HC, LLC serves as the general partner of QVP VIII-HC and may be deemed to have voting and dispositive power over the shares held by QVP VIII-HC. Qiming GP VIII-HC, LLC disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
Common shares sold 100,117 shares Reported sales on November 11, 2026, across eight transaction rows
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
dispositive power regulatory
"may be deemed to have voting and dispositive power"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
beneficial ownership regulatory
"disclaims beneficial ownership of such shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"except to the extent of its proportionate pecuniary interest therein"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ALMR shares were sold on November 11, 2026?

The reporting persons reported sales of 100,117 ALMR common shares on November 11, 2026. The shares were held of record by Qiming Managing Directors Fund VI, L.P.; Qiming Venture Partners VI, L.P.; Qiming Venture Partners VIII Investments, LLC; and Qiming Venture Partners VIII-HC, L.P. No Rule 10b5-1 plan is reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Qiming Corporate GP VI, Ltd.

(Last)(First)(Middle)
C/O MAPLES CORPORATE SERVICES LIMITED
PO BOX 309

(Street)
UGLAND HOUSEGRAND CAYMANKY1-1104

(City)(State)(Zip)

CAYMAN ISLANDS

(Country)
2. Issuer Name and Ticker or Trading Symbol
Alamar Biosciences, Inc. [ ALMR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/11/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/11/2026S1,694D$29.34(1)157,273ISee footnote(2)
Common Stock11/11/2026S56D$30.63(3)157,217ISee footnote(2)
Common Stock11/11/2026S62,944D$29.34(1)5,844,859ISee footnote(4)
Common Stock11/11/2026S2,084D$30.63(3)5,842,775ISee footnote(4)
Common Stock11/11/2026S14,687D$29.34(1)1,363,787ISee footnote(5)
Common Stock11/11/2026S486D$30.63(3)1,363,301ISee footnote(5)
Common Stock11/11/2026S17,584D$29.34(1)1,632,770ISee footnote(6)
Common Stock11/11/2026S582D$30.63(3)1,632,188ISee footnote(6)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
1. Name and Address of Reporting Person*
Qiming Corporate GP VI, Ltd.

(Last)(First)(Middle)
C/O MAPLES CORPORATE SERVICES LIMITED
PO BOX 309

(Street)
UGLAND HOUSEGRAND CAYMANKY1-1104

(City)(State)(Zip)

CAYMAN ISLANDS

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Qiming Managing Directors Fund VI, L.P.

(Last)(First)(Middle)
C/O MAPLES CORPORATE SERVICES LIMITED
PO BOX 309

(Street)
UGLAND HOUSEGRAND CAYMANKY1-1104

(City)(State)(Zip)

CAYMAN ISLANDS

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Qiming Venture Partners VI, L.P.

(Last)(First)(Middle)
C/O MAPLES CORPORATE SERVICES LIMITED
PO BOX 309

(Street)
UGLAND HOUSEGRAND CAYMANKY1-1104

(City)(State)(Zip)

CAYMAN ISLANDS

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Qiming GP VIII, LLC

(Last)(First)(Middle)
C/O MAPLES CORPORATE SERVICES LIMITED
PO BOX 309

(Street)
UGLAND HOUSEGRAND CAYMANKY1-1104

(City)(State)(Zip)

CAYMAN ISLANDS

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Qiming Venture Partners VIII Investments, LLC

(Last)(First)(Middle)
C/O MAPLES CORPORATE SERVICES LIMITED
PO BOX 309

(Street)
UGLAND HOUSEGRAND CAYMANKY1-1104

(City)(State)(Zip)

CAYMAN ISLANDS

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Qiming GP VIII-HC, LLC

(Last)(First)(Middle)
C/O MAPLES CORPORATE SERVICES LIMITED
PO BOX 309

(Street)
UGLAND HOUSEGRAND CAYMANKY1-1104

(City)(State)(Zip)

CAYMAN ISLANDS

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Qiming Venture Partners VIII-HC, L.P.

(Last)(First)(Middle)
C/O MAPLES CORPORATE SERVICES LIMITED
PO BOX 309

(Street)
UGLAND HOUSEGRAND CAYMANKY1-1104

(City)(State)(Zip)

CAYMAN ISLANDS

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.40 to $30.22, inclusive. The reporting person undertakes to provide to Alamar Biosciences, Inc., any security holder of Alamar Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes (1) and (3) to this Form 4.
2. These shares are held of record by Qiming Managing Directors Fund VI, L.P. ("Qiming Managing Directors"). Qiming Corporate GP VI, Ltd. ("Qiming Corporate") serves as the general partner of Qiming Managing Directors and may be deemed to have voting and dispositive power over the shares held by Qiming Managing Directors. Qiming Corporate disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.38 to $30.94, inclusive.
4. These shares are held of record by Qiming Venture Partners VI, L.P., ("Qiming Venture Partners VI"). Qiming Corporate, through one intermediary, serves as the indirect general partner of Qiming Venture Partners VI and may be deemed to have voting and dispositive power over the shares held by Qiming Venture Partners VI. Qiming Corporate disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
5. These shares are held of record by Qiming Venture Partners VIII Investments, LLC ("QVP VIII LLC"). Qiming GP VIII, LLC, through two parallel intermediaries, serves as the indirect general partner of QVP VIII LLC and may be deemed to have voting and dispositive power over the shares held by QVP VIII LLC. Qiming GP VIII, LLC disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
6. These shares are held of record by Qiming Venture Partners VIII-HC, L.P. ("QVP VIII-HC"). Qiming GP VIII-HC, LLC serves as the general partner of QVP VIII-HC and may be deemed to have voting and dispositive power over the shares held by QVP VIII-HC. Qiming GP VIII-HC, LLC disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
Qiming GP VIII, LLC By: /s/ Ho Man LAM/Authorized Signatory11/13/2026
Qiming Venture Partners VIII Investments, LLC By: /s/ Ho Man LAM/Manager11/13/2026
Qiming GP VIII-HC, LLC By: /s/ Ho Man LAM/Authorized Signatory11/13/2026
Qiming Venture Partners VIII-HC, L.P. By: /s/ Ho Man LAM/Authorized Signatory11/13/2026
Qiming Corporate GP VI, Ltd By: /s/ Ho Man LAM/Authorized Signatory11/13/2026
Qiming Managing Directors Fund VI, L.P. By: /s/ Ho Man LAM/Authorized Signatory11/13/2026
Qiming Venture Partners VI, L.P. By: /s/ Ho Man LAM/Authorized Signatory11/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading